Phase I Study of Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2019
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 11 Apr 2019 Status changed from active, no longer recruiting to completed.
- 06 Feb 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2021.
- 06 Feb 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.